Roivant Sciences Ltd Ordinary Shares ROIV 深 沪
已收盘 12-12 16:00:00 美东时间
22.10
+0.760
+3.56%
华盛通- 最 高22.445
- 今 开21.77
- 成交量 1239.45万股
- 最 低 21.39
- 昨 收 21.34
- 总市值 150.94亿
- 52周最高 22.445
- 市盈率 静 --
- 换手率 1.81%
- 52周最低 8.73
- 委 比 -57.39%
- 总股本 6.83亿
- 历史最高 22.445
- 量 比 1.64
- 振 幅 4.94%
- 历史最低 2.52
- 每 手 1
- 风险率 3.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股盘后 | Lululemon Athletica涨10.71%，阿利根尼涨3.86%
Lululemon Athletica涨10.71%；阿利根尼涨3.86%；Roivant Sciences Ltd Ordinary Shares涨2.61%
12-12 07:12
Roivant Sciences Highlights Pipeline Progress at Investor Day
An announcement from Roivant Sciences ( ($ROIV) ) is now available. On December...
12-11 21:19
Roivant Says Three New Drugs Could Hit the Market in the Next Three Years, Speeds Up Trial Timelines as It Prepares for Major Product Launches ,
Roivant (NASDAQ:ROIV) today is hosting an Investor Day in New York City. Roivant leadership will highlight key pipeline updates and provide an update on the Company's strategy for long-term value creation."We are at
12-11 20:35
Immunovant drops 7%, prices $550M stock offering
Clinical-stage immunology company Immunovant (IMVT) priced an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of ~$550M. Roivant Sciences, the company’s contro...
12-11 18:48
Immunovant Announces Pricing of $550 Million Common Stock Financing
Immunovant, a clinical-stage immunology company, announced the pricing of an underwritten offering of its common stock, expecting gross proceeds of approximately $550 million. The funds are intended to support its operations and capital expenditures through the potential commercial launch of IMVT-1402 for Graves' Disease. Immunovant is offering 26.2 million shares at $21.00 per share, with the offering expected to close on December 12, 2025. Leer...
12-11 06:29
美股盘后 | Nu Holdings涨3.63%，Atlassian公共涨3.31%
Nu Holdings涨3.63%；Atlassian公共涨3.31%；华纳兄弟探索频道涨3.21%
11-14 07:10
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $26
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $25 to $26.
11-12 03:59
Roivant Sciences Q2 Adj. EPS $(0.28) Beats $(0.33) Estimate, Sales $1.571M Miss $6.947M Estimate
Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.33) by 16.17 percent. This is a 12 percent decrease over losses of $(0.25) per share from the
11-10 20:02
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
